MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/mib.0b013e318280b169

Медицинская библиотека · Inflammatory bowel diseases · 2013

The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α.

Ueda Naoyasu, Tsukamoto Hiroshi, Mitoma Hiroki, Ayano Masahiro, Tanaka Atsushi, Ohta Shun-ichiro, Inoue Yasushi, Arinobu Yojiro, Niiro Hiroaki, Akashi Koichi, Horiuchi Takahiko

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Anti-tumor necrosis factor α (anti-TNF-α) agents have been successfully applied for the treatment of rheumatoid arthritis, Crohn's disease, and other chronic inflammatory diseases. Not only the neutralization of soluble TNF-α but also the effect on transmembrane TNF-α is important mechanisms of action of anti-TNF-α agents. This study investigated the cytotoxic effects of new anti-TNF-α agents, certolizumab pegol and golimumab, which are mediated by transmembrane TNF-α.

METHODS

Transmembrane TNF-α-expressing Jurkat T cells that did not express TNF receptors were used. The binding ability of each anti-TNF-α agent to transmembrane TNF-α, antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and the apoptotic effect were examined.

RESULTS

Certolizumab pegol and golimumab bound to transmembrane TNF-α. Golimumab induced antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, which was comparable to infliximab and adalimumab. However, certolizumab pegol did not induce antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity. Certolizumab pegol directly induced nonapoptotic cell death in transmembrane TNF-α-expressing cells. Golimumab induced a weaker apoptotic effect than infliximab and adalimumab.

CONCLUSIONS

The cytotoxic effects of anti-TNF-α agents on TNF-α-expressing cells are considered to be associated with the clinical effect of these agents on granulomatous diseases. The direct cytotoxic effect of certolizumab pegol on TNF-α-producing cells may contribute to its clinical efficacy in Crohn's disease. Golimumab may be less effective for granulomatous diseases.

Для цитирования: Ueda Naoyasu, Tsukamoto Hiroshi, Mitoma Hiroki, Ayano Masahiro, Tanaka Atsushi, Ohta Shun-ichiro, Inoue Yasushi, Arinobu Yojiro, Niiro Hiroaki, Akashi Koichi, Horiuchi Takahiko. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α.. Inflammatory bowel diseases. 2013. DOI: 10.1097/mib.0b013e318280b169.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.